Latham & Watkins Advises Underwriters in TELA Bio, Inc.’s Public Offering of Common Stock

Capital markets team represented the underwriters in the offering by the commercial-stage medical technology company.

June 26, 2020

TELA Bio, Inc. (TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, has announced the pricing of its underwritten public offering of 3 million shares of its common stock at a public offering price of US$16 per share for gross proceeds of US$48 million, before underwriting discounts and commissions. In addition, TELA has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock in the offering. All shares of common stock are being offered by TELA. The offering is expected to close on June 30, 2020, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a corporate team led by New York partners Marc Jaffe and Nathan Ajiashvili, with associates Taylor Stevens, Daniel Walder, and Isabelle Sawhney.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.